Breaking Down Registration, Testing and Agent Service Fees: A Practical Estimate

1. Key takeaways

The official fee amounts for medical device registration in Iran are not published in a unified public channel, and the figures given by different sources vary considerably. GRZAN’s judgment is that companies should not budget from any single source’s fee number, but should instead estimate according to the fee structure: four major categories — registration-related fees, testing and laboratory fees, local agent and service fees, and document legalisation and translation fees. The structure is manageable; the absolute numbers must follow the current actual quotations. Reading the market this way changes the budgeting conversation: instead of arguing about whose number is right, the company asks which category each cost belongs to, what drives that category, and where the realistic room for compression lies. Registration-related fees are the least controllable because the authority does not publish them; testing fees can be compressed by eliminating duplicate tests; agent service fees carry the widest variation because they depend on exclusivity and performance binding; and legalisation and translation costs have the least flexibility but can be reduced per unit by batching. On top of the fees themselves, the timeline matters more to total cost than any single fee item, because each additional review round carries its own set of costs. All figures in this article are practical estimates, pending verification against current quotations.

• Official fee amounts are not published in a stable public channel; figures from different sources differ widely.
• Budget by fee structure: registration-related fees, testing fees, local agent and service fees, and document legalisation and translation fees.
• Testing fees are the most compressible category, mainly by eliminating duplicate tests through gap analysis.
• Agent service fees vary the most, depending on exclusivity terms and performance binding; legalisation and translation costs are the least flexible but can be batched.
• A longer registration cycle often costs more than any single fee item, so compressing the timeline is compressing the cost.

2. Legal basis

The budgeting approach described here rests on the absence of a public fee register, on the VAT treatment of services, and on the corporate income tax framework that shapes local partner pricing. The items below state each basis and its verification status.

1. Official fee amounts: Iran does not maintain a stably accessible English register of current fee amounts and processing times — see public industry database descriptions; specific fee amounts are a practical estimate and must follow the current actual quotations of the competent authority and the local entity.
2. VAT Law (approved 23 May 2021, effective 3 January 2022): both services and supplies of goods fall within the scope of VAT, with a standard rate of 9%, so fee estimates must include the tax burden.
3. Direct Taxes Law (1987), Article 105: corporate income tax at 25%, which shapes the pricing behaviour of local partners.

3. Expert insights

Insight 1: the four fee categories differ in controllability. Testing and laboratory fees are the easiest to compress by reducing duplicate testing — which is exactly where the value of a gap analysis lies: every test that an existing report can substitute for is a line item removed from the budget. Document legalisation and translation fees have the least flexibility, because each document must be processed, but their unit cost falls when documents are handled in batches. Local agent service fees have the widest variation, depending on the exclusivity terms and how the agent’s compensation is bound to performance. Registration-related fees are the least controllable, because the authority does not publish them. Knowing which category a cost belongs to therefore tells the company where negotiation is worthwhile and where it is not.

Insight 2: the timeline affects total cost more than the fees do. Public industry sources estimate the full Iranian registration cycle within a wide range, from 6 months to 18 months, with the difference driven mainly by the number of review rounds. Each additional deficiency round adds its own costs — renewed document preparation, additional legalisation, extended agent engagement, delayed revenue. One more round often exceeds the cost of any single fee item. Compressing the cycle is therefore the same as compressing the cost, and the highest-leverage move is a complete, well-formed dossier at first submission.

Insight 3: the tax burden must be counted into service fees. Local agent services fall within the scope of VAT. If a quotation excludes tax, the actual expenditure will be higher than expected. Before comparing quotations from different agents, the company should normalise them to the same tax basis; a cheaper-looking quotation that excludes VAT may in fact be the more expensive one once the statutory rate is applied. Normalising on the same basis also prevents the wider budget error of mixing tax-inclusive and tax-exclusive figures within a single cost table, which distorts category totals and makes the contingency percentages unreliable.

4. Practical recommendations

• Build the budget table by the four major categories: registration, testing, agent services, and legalisation and translation, with a 15% contingency reserved for each category.
• Use gap analysis as a cost-reduction tool: eliminating duplicate tests is the most effective single action for compressing testing fees.
• Clarify whether quotations include tax: confirm with the local agent whether the quoted price includes VAT.
• Do not rely on a single source’s figures: before any external commitment, re-verify the numbers against the current actual quotations.

5. Verification checklist

• □ The budget table has been built by the four major categories with a contingency reserved
• □ The gap analysis is complete and duplicate test items have been eliminated
• □ It is clear whether the local agent’s quotation includes VAT
• □ Official fee amounts have been re-verified against current actual quotations, without reliance on a single source
• □ The budget table notes that all figures are practical estimates and not commitments

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team coordinates local import arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com